NCT02678780

Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Grupo Espanol de Tumores Neuroendocrinos · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohort A) or gastrointestinal tract after progression to somatostatin analogues (cohort B).

Detailed description

Trial to assess the efficacy of Lenvatinib in metastatic neuroendocrine tumor. The primary endpoint of the study is overall response rate (ORR) by RECIST v 1.1 upon central radiologic assessment. Number of patients: 110 patients Estimated duration of subject participation: 24 months

Conditions

• Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	Lenvatinib

Timeline

• Start date: 2015-10-01
• Primary completion: 2017-12-01
• Completion: 2020-08-01
• First posted: 2016-02-10
• Last updated: 2025-07-24
• Results posted: 2025-07-24

Locations

22 sites across 4 countries: Austria, Italy, Spain, United Kingdom